Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia

5Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Background: Darunavir/ritonavir is a potent PI with a high genetic barrier and pharmacological robustness favourably investigated as monotherapy. Whether darunavir could be dose reduced in the context of monotherapy deserves investigation. Methods: Patients with HIV suppressed viraemia (plasma viral load <50 copies/mL for 12 months) under ART who had switched to darunavir/ritonavir monotherapy at 600/100 mg/day between 2013 and 2015 were included in this observational 48 week single-centre study. The primary outcome was the proportion of patients with virological success (defined as plasma viral load <50 copies/mL) at week 24. Secondary outcomes included treatment strategy success and resistance. Results: Thirty-one patients were included with the following baseline characteristics [median (IQR)]: age 52 years (47-57), CD4+ 649 cells/mm3 (463-813), ART duration 16.3 years (9.2-22.3), nadir CD4+ 195 cells/mm3 (144-261) and duration of HIV suppression 7.8 years (4.8-9.7). Prior to switch, ART consisted of PI monotherapy for 28 of 31 patients [darunavir/ritonavir 800/100 mg/day (n = 26), lopinavir/ritonavir (n = 1) and atazanavir/ritonavir (n = 1)] and a triple drug regimen for 3 of 31 patients. Within the 48 weeks of follow-up, no virological failure occurred and two patients discontinued 600/100 mg of darunavir/ritonavir due to side effects at week 16 and 40, leading to a virological suppression rate of 100% (95% CI = 89-100) at weeks 24 and 48. Strategy success rates were 96.8% (95% CI = 83.3-99.9) at week 24 and 93.5% (95% CI = 78.6-99.2) at week 48. Median (IQR) Ctrough values of 800/100 mg of darunavir/ritonavir and 600/100 mg of darunavir/ritonavir were 1537 ng/mL (1286-1724) and 1255 ng/mL (873-2161), respectively. Conclusions: A lower dose of darunavir/ritonavir used as monotherapy (600/100 mg/day) was highly effective in virologically suppressed HIV-infected patients. Further studies are needed to confirm these data.

References Powered by Scopus

Initiation of antiretroviral therapy in early asymptomatic HIV infection

2265Citations
N/AReaders
Get full text

Antiretroviral therapy for the prevention of HIV-1 transmission

1279Citations
N/AReaders
Get full text

Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study

216Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Effectiveness, safety, and tolerability of a switch to dual therapy with dolutegravir plus cobicistat-boosted darunavir in treatment-experienced patients with human immunodeficiency virus

15Citations
N/AReaders
Get full text

Dual Antiretroviral Therapy—All Quiet Beneath the Surface?

13Citations
N/AReaders
Get full text

Simplifying ARV Therapy in the Setting of Resistance

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Seang, S., Schneider, L., Nguyen, T., Lê, M. P., Soulie, C., Calin, R., … Katlama, C. (2018). Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. Journal of Antimicrobial Chemotherapy, 73(2), 490–493. https://doi.org/10.1093/jac/dkx417

Readers over time

‘18‘19‘20‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Lecturer / Post doc 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

71%

Nursing and Health Professions 1

14%

Immunology and Microbiology 1

14%

Save time finding and organizing research with Mendeley

Sign up for free
0